Latest Breaking News On - Centre for affective disorders - Page 1 : comparemela.com

Theracryf : Annual Report and Accounts 2023-24

THERACRYF PLC ANNUAL REPORT & FINANCIAL STATEMENTS 2024 FOCUSSING ON ONCOLOGY AND NEUROPSYCHIATRY .

City ofUnited kingdomEvgen pharmaSusan clement daviesAllan youngBarry clareSusan fodenChronos therapeutics ltdKings college londonErasmus medical centreCentre for affective disordersInstitute of psychiatryClement daviesTherapeutics ltdProfessor allan youngMood disorders

Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Programme

Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Programme
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomIhre chancenIndiens wirtschaftAllan youngGraeme duncanHead of clinical development at neurocentrxInternational society for affective disorders conferenceInstitute of psychiatryWorld university rankingsKing college londonResearch excellence frameworkPsychology neuroscience at king college londonCentre for affective disordersMood disorders

Janssen reveals new Spravato data

Janssen reveals new Spravato data
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofAllan youngMarjorie wallaceJanssen pharmaceutical companies of johnsonRoyal college of psychiatrists international congressInstitute of psychiatryCentre for affective disordersKing college londonJanssen pharmaceutical companiesRoyal collegePsychiatrists internationalAffective disordersCollege london

Neurocentrx Provides Update on Clinical Progress of Lead Programme, Keticap, an Oral Ketamine Formulation for the Treatment of Mood Disorders

Phase 1 completed with data readout to be reported in Q3 2023 Preliminary data indicates good safety and tolerance up to highest dose Neurocentrx (the Company), a biopharmaceutical company specialising

City ofUnited kingdomCarmel reillyAllan youngGraeme duncanNeurocentrx the companyKing college londonHead of clinical development at neurocentrxRegulatory agencyCentre for affective disordersProfessor allan youngAffective disordersUnited kingdom medicinesClinical developmentUnited kingdom basedInstinctif partners

Neurocentrx Provides Update on Clinical Progress of Lead Programme, Keticap®, an Oral Ketamine Formulation for the Treatment of Mood Disorders

Neurocentrx Provides Update on Clinical Progress of Lead Programme, Keticap®, an Oral Ketamine Formulation for the Treatment of Mood Disorders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofCarmel reillyAllan youngGraeme duncanNeurocentrx the companyKing college londonHead of clinical development at neurocentrxRegulatory agencyCentre for affective disordersProfessor allan youngAffective disordersUnited kingdom medicinesClinical developmentUnited kingdom basedInstinctif partners